{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:09:03Z","timestamp":1791374943609,"version":"4.3.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014679","name":"CRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester","doi-asserted-by":"publisher","award":["C8742\/A18097"],"award-info":[{"award-number":["C8742\/A18097"]}],"id":[{"id":"10.13039\/501100014679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014679","name":"CRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester","doi-asserted-by":"publisher","award":["C8742\/A18097"],"award-info":[{"award-number":["C8742\/A18097"]}],"id":[{"id":"10.13039\/501100014679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014679","name":"CRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester","doi-asserted-by":"publisher","award":["C8742\/A18097"],"award-info":[{"award-number":["C8742\/A18097"]}],"id":[{"id":"10.13039\/501100014679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000832","name":"Dowager Countess Eleanor Peel Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000832","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manchester Academic Health Sciences centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Vestibular schwannoma (VS) can present several management challenges for the clinician. Their unpredictable potential for growth creates uncertainty regarding when active treatment should be initiated, and once growth is confirmed which treatment option should be adopted, notably surgery or radiotherapy, and in particular stereotactic radiosurgery (SRS). The obvious benefits of SRS would ideally come with the ability to reliably predict long-term radiosurgery response\/failure. Differentiation from temporary post-treatment phenomena such as transient tumour expansion or reactive swelling remains an unmet need. More powerful again would be the pre-treatment identification of which tumours will respond to radiosurgery and which will not. Over the past decade, there has been emerging interest in the development of non-invasive biomarkers, including imaging, for predicting growth and treatment response in VS. Alongside clinical radiographic predictors for VS growth such as extracanalicular tumour location and growth in the first year, studies have shown potential promise for advanced MRI and blood-based biomarkers that capture pathophysiological mechanism behind VS growth. Emerging interest in\n                    <jats:italic>radiomics<\/jats:italic>\n                    -based analyses of routinely acquired MRI, and the use of physiological imaging techniques such as dynamic-contrast enhanced MRI for pre- and post-treatment evaluation of tumour microvasculature and microstructure holds promise for revolutionizing this area. This article explores the current state of identifying VS growth at initial presentation, predicting treatment response to SRS and detecting early treatment failure, and finally the potential for developing more personalized patient selection for drug therapies, including bevacizumab, as well as emerging novel therapeutics for these tumours.\n                  <\/jats:p>","DOI":"10.1007\/s00701-025-06522-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T01:58:10Z","timestamp":1745287090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Emerging strategies for the prediction of behaviour, growth, and treatment response in vestibular schwannoma"],"prefix":"10.1007","volume":"167","author":[{"given":"Daniel","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-loh","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Djoukhadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal J.","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar N.","family":"Pathmanaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Coope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"6522_CR1","doi-asserted-by":"publisher","first-page":"vdae094","DOI":"10.1093\/noajnl\/vdae094","volume":"6","author":"B Alfaifi","year":"2024","unstructured":"Alfaifi B, Hinz R, Jackson A, Wadeson A, Pathmanaban ON, Hammerbeck-Ward C, Rutherford SA, King AT, Lewis D, Coope DJ (2024) Evidence for inflammation in normal appearing brain regions in patients with growing sporadic vestibular schwannoma: a PET study. Neuro-Oncology Adv 6:vdae094","journal-title":"Neuro-Oncology Adv"},{"issue":"6","key":"6522_CR2","first-page":"437","volume":"56","author":"DB Almeida-Freitas","year":"2014","unstructured":"Almeida-Freitas DB, Pinho MC, Otaduy MCG, Braga HF, Meira-Freitas D, Da Costa LC (2014) Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging. Neuroradiology 56(6):437\u2013443","journal-title":"Neuroradiology"},{"issue":"6","key":"6522_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MAO.0000000000002272","volume":"40","author":"JM Anton-Rodriguez","year":"2019","unstructured":"Anton-Rodriguez JM, Lewis D, Djoukhadar I et al (2019) [18fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma. Otol Neurotol 40(6):826\u2013835","journal-title":"Otol Neurotol"},{"issue":"2","key":"6522_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/neuonc\/noae187","volume":"27","author":"A Balossier","year":"2024","unstructured":"Balossier A, Olteanu M, Delsanti C, Troude L, Thomassin J-M, Roche P-H, Chavent M, R\u00e9gis J (2024) Dynamics of tumor evolution after Gamma Knife radiosurgery for sporadic vestibular schwannoma: Defining volumetric patterns characterizing individual trajectory. Neuro Oncol 27(2):545\u2013556","journal-title":"Neuro Oncol"},{"issue":"47","key":"6522_CR5","doi-asserted-by":"publisher","first-page":"19059","DOI":"10.1073\/pnas.1318022110","volume":"110","author":"TT Batchelor","year":"2013","unstructured":"Batchelor TT, Gerstner ER, Emblem KE et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 110(47):19059\u201319064","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6522_CR77","doi-asserted-by":"publisher","unstructured":"Becker A-L, Scholle L, Klause CH, Staege MS, Strauss C, Otto M, Rampp S, Scheller C, Leisz S (2024) Correlation of immunomodulatory cytokines with tumor volume and cerebrospinal fluid in vestibular schwannoma patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16173002","DOI":"10.3390\/cancers16173002"},{"issue":"1","key":"6522_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajmg.a.34359","volume":"158A","author":"JO Blakeley","year":"2012","unstructured":"Blakeley JO, Evans DG, Adler J et al (2012) Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet Part A 158A(1):24\u201341","journal-title":"Am J Med Genet Part A"},{"key":"6522_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3817","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2015.64.3817","journal-title":"J Clin Oncol"},{"issue":"14","key":"6522_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 34(14):1669\u20131675","journal-title":"J Clin Oncol"},{"issue":"1","key":"6522_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/iao.2023.22581","volume":"19","author":"O Borysenko","year":"2023","unstructured":"Borysenko O, Melnykov O, Prilutskaya A, Buracovschi M (2023) Immunological analysis of vestibular schwannoma patients. J Int Adv Otol 19(1):1\u20134","journal-title":"J Int Adv Otol"},{"issue":"3","key":"6522_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/neuros\/nyx027","volume":"81","author":"G Bowden","year":"2017","unstructured":"Bowden G, Cavaleri J, Monaco EIII, Niranjan A, Flickinger J, Lunsford LD (2017) Cystic vestibular schwannomas respond best to radiosurgery. Neurosurgery 81(3):490\u2013497","journal-title":"Neurosurgery"},{"issue":"6","key":"6522_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3174\/ajnr.A5144","volume":"38","author":"A Camargo","year":"2017","unstructured":"Camargo A, Schneider T, Liu L, Pakpoor J, Kleinberg L, Yousem DM (2017) Pretreatment ADC values predict response to radiosurgery in vestibular schwannomas. Am J Neuroradiol 38(6):1200\u20131205","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"6522_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11060-023-04280-z","volume":"162","author":"H-C Chang","year":"2023","unstructured":"Chang H-C, You WC, Shen C-C, Chen YJ, Sun M-H, Sheu M-L, Pan L-Y, Sheehan J, Su K-C, Pan H-C (2023) Using the deformity index of vital structures to predict outcome of patients with large vestibular schwannomas after Gamma Knife radiosurgery. J Neurooncol 162(1):179\u2013189","journal-title":"J Neurooncol"},{"issue":"1","key":"6522_CR13","doi-asserted-by":"publisher","first-page":"vdad099","DOI":"10.1093\/noajnl\/vdad099","volume":"5","author":"S Chiranth","year":"2023","unstructured":"Chiranth S, Langer SW, Poulsen HS, Urup T (2023) A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis. Neuro-oncology Adv 5(1):vdad099","journal-title":"Neuro-oncology Adv"},{"issue":"Suppl","key":"6522_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3171\/2012.7.GKS121003","volume":"117","author":"CC Chuang","year":"2012","unstructured":"Chuang CC, Chang CS, Tyan YS, Chuang KS, Tu HT, Huang CF (2012) Use of apparent diffusion coefficients in evaluating the response of vestibular schwannomas to Gamma Knife surgery. J Neurosurg 117(Suppl):63\u201368","journal-title":"J Neurosurg"},{"issue":"1","key":"6522_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00129492-200101000-00016","volume":"22","author":"A Gomez-Brouchet","year":"2001","unstructured":"Gomez-Brouchet A, Delisle MB, Cognard C, Bonafe A, Charlet JP, Deguine O, Fraysse B (2001) Vestibular schwannomas: Correlations between magnetic resonance imaging and histopathologic appearance. Otol Neurotol 22(1):79\u201386","journal-title":"Otol Neurotol"},{"issue":"4","key":"6522_CR16","doi-asserted-by":"publisher","first-page":"fcad197","DOI":"10.1093\/braincomms\/fcad197","volume":"5","author":"GE Gregory","year":"2023","unstructured":"Gregory GE, Jones AP, Haley MJ et al (2023) The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma. Brain Commun 5(4):fcad197","journal-title":"Brain Commun"},{"key":"6522_CR17","doi-asserted-by":"publisher","first-page":"109287","DOI":"10.1016\/j.clim.2023.109287","volume":"249","author":"GE Gregory","year":"2023","unstructured":"Gregory GE, Munro KJ, Couper KN, Pathmanaban ON, Brough D (2023) The NLRP3 inflammasome as a target for sensorineural hearing loss. Clin Immunol 249:109287. https:\/\/doi.org\/10.1016\/j.clim.2023.109287","journal-title":"Clin Immunol"},{"issue":"3","key":"6522_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1749-4486.2008.01705.x","volume":"33","author":"D Hajioff","year":"2008","unstructured":"Hajioff D, Raut VV, Walsh RM, Bath AP, Bance ML, Guha A, Tator CH, Rutka JA (2008) Conservative management of vestibular schwannomas: third review of a 10-year prospective study. Clin Otolaryngol 33(3):255\u2013259","journal-title":"Clin Otolaryngol"},{"issue":"1","key":"6522_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14737175.2018.1399795","volume":"18","author":"J Halliday","year":"2018","unstructured":"Halliday J, Rutherford SA, McCabe MG, Evans DG (2018) An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev Neurother 18(1):29\u201339","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"6522_CR20","doi-asserted-by":"publisher","first-page":"vdaa023","DOI":"10.1093\/noajnl\/vdaa023","volume":"2","author":"CJ Hannan","year":"2020","unstructured":"Hannan CJ, Lewis D, O\u2019Leary C, Donofrio CA, Evans DG, Roncaroli F, Brough D, King AT, Coope D, Pathmanaban ON (2020) The inflammatory microenvironment in vestibular schwannoma. Neuro-oncology Adv 2(1):vdaa023","journal-title":"Neuro-oncology Adv"},{"issue":"3","key":"6522_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1227\/neu.0000000000002252","volume":"92","author":"CJ Hannan","year":"2023","unstructured":"Hannan CJ, Lewis D, O\u2019Leary C et al (2023) Increased circulating chemokines and macrophage recruitment in growing vestibular schwannomas. Neurosurgery 92(3):581\u2013589","journal-title":"Neurosurgery"},{"issue":"10","key":"6522_CR22","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/MAO.0000000000001219","volume":"37","author":"JB Hunter","year":"2016","unstructured":"Hunter JB, Francis DO, O\u2019Connell BP, Kabagambe EK, Bennett ML, Wanna GB, Rivas A, Thompson RC, Haynes DS (2016) Single institutional experience with observing 564 vestibular schwannomas: factors associated with tumor growth. Otol Neurotol 37(10):1630\u20131636","journal-title":"Otol Neurotol"},{"key":"6522_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08517-1","author":"I Hwang","year":"2022","unstructured":"Hwang I, Choi SH, Kim JW, Yeon EK, Lee JY, Yoo R-E, Kang KM, Yun TJ, Kim J-H, Sohn C-H (2022) Response prediction of vestibular schwannoma after gamma-knife radiosurgery using pretreatment dynamic contrast-enhanced MRI: a prospective study. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-021-08517-1","journal-title":"Eur Radiol"},{"key":"6522_CR24","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1016\/j.wneu.2022.07.058","volume":"166","author":"T Itoyama","year":"2022","unstructured":"Itoyama T, Nakaura T, Hamasaki T, Takezaki T, Uentani H, Hirai T, Mukasa A (2022) Whole tumor radiomics analysis for risk factors associated with rapid growth of vestibular schwannoma in contrast-enhanced T1-weighted images. World Neurosurg 166:e572\u2013e582","journal-title":"World Neurosurg"},{"key":"6522_CR72","doi-asserted-by":"crossref","unstructured":"Jones AP, Haley MJ, Gregory GE, Hannan CJ, Simmons AK, Bere LD, Lewis DG, Oliveira P, Smith MJ, King AT (2024) High-dimensional imaging of vestibular schwannoma reveals distinctive immunological networks across histomorphic niches in NF2-related schwannomatosis","DOI":"10.1101\/2024.04.09.588593"},{"issue":"01","key":"6522_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-0039-1678708","volume":"81","author":"M Kleijwegt","year":"2020","unstructured":"Kleijwegt M, Bettink F, Malessy M, Putter H, van der Mey A (2020) Clinical predictors leading to change of initial conservative treatment of 836 vestibular schwannomas. J Neurol Surg Part B Skull Base 81(01):15\u201321","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"6522_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MAO.0000000000001026","volume":"37","author":"G Kontorinis","year":"2016","unstructured":"Kontorinis G, Crowther JA, Iliodromiti S, Taylor WAS, Locke R (2016) Neutrophil to lymphocyte ratio as a predictive marker of vestibular schwannoma growth. Otol Neurotol 37:580\u2013585","journal-title":"Otol Neurotol"},{"key":"6522_CR79","doi-asserted-by":"publisher","unstructured":"Kouzel Martinez F, Graffeo CS, Carlstrom LP, Link MJ (2021) Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2021-241834","DOI":"10.1136\/bcr-2021-241834"},{"issue":"5","key":"6522_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.3171\/2018.6.JNS18516","volume":"131","author":"PPJH Langenhuizen","year":"2018","unstructured":"Langenhuizen PPJH, Zinger S, Hanssens PEJ, Kunst HPM, Mulder JJS, Leenstra S, de With PHN, Verheul JB (2018) Influence of pretreatment growth rate on Gamma Knife treatment response for vestibular schwannoma: a volumetric analysis. J Neurosurg 131(5):1405\u20131412","journal-title":"J Neurosurg"},{"issue":"4","key":"6522_CR28","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/mp.14042","volume":"47","author":"PPJH Langenhuizen","year":"2020","unstructured":"Langenhuizen PPJH, Sebregts SHP, Zinger S, Leenstra S, Verheul JB, de With PHN (2020) Prediction of transient tumor enlargement using MRI tumor texture after radiosurgery on vestibular schwannoma. Med Phys 47(4):1692\u20131701","journal-title":"Med Phys"},{"issue":"10","key":"6522_CR29","doi-asserted-by":"publisher","first-page":"e1321","DOI":"10.1097\/MAO.0000000000002886","volume":"41","author":"PPJH Langenhuizen","year":"2020","unstructured":"Langenhuizen PPJH, Zinger S, Leenstra S, Kunst HPM, Mulder JJS, Hanssens PEJ, de With PHN, Verheul JB (2020) Radiomics-based prediction of long-term treatment response of vestibular schwannomas following stereotactic radiosurgery. Otol Neurotol 41(10):e1321\u2013e1327","journal-title":"Otol Neurotol"},{"issue":"3","key":"6522_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/neuonc\/noy177","volume":"21","author":"D Lewis","year":"2019","unstructured":"Lewis D, Roncaroli F, Agushi E et al (2019) Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro Oncol 21(3):314\u2013325","journal-title":"Neuro Oncol"},{"issue":"5","key":"6522_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3171\/2020.3.JNS193230","volume":"134","author":"D Lewis","year":"2020","unstructured":"Lewis D, Donofrio CA, O\u2019Leary C et al (2020) The microenvironment in sporadic and neurofibromatosis type II\u2013related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study. J Neurosurg 134(5):1419\u20131429","journal-title":"J Neurosurg"},{"issue":"1","key":"6522_CR32","doi-asserted-by":"publisher","first-page":"15712","DOI":"10.1038\/s41598-021-95022-6","volume":"11","author":"D Lewis","year":"2021","unstructured":"Lewis D, McHugh DJ, Li K-L, Zhu X, Mcbain C, Lloyd SK, Jackson A, Pathmanaban ON, King AT, Coope DJ (2021) Detection of early changes in the post-radiosurgery vestibular schwannoma microenvironment using multinuclear MRI. Sci Rep 11(1):15712","journal-title":"Sci Rep"},{"issue":"2","key":"6522_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/neuonc\/nov168","volume":"18","author":"KL Li","year":"2016","unstructured":"Li KL, Djoukhadar I, Zhu X, Zhao S, Lloyd S, McCabe M, McBain C, Evans DG, Jackson A (2016) Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro Oncol 18(2):275\u2013282","journal-title":"Neuro Oncol"},{"key":"6522_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.28842","author":"K-L Li","year":"2021","unstructured":"Li K-L, Lewis D, Coope DJ et al (2021) The LEGATOS technique: a new tissue-validated dynamic contrast-enhanced MRI method for whole-brain, high-spatial resolution parametric mapping. Magn Reson Med. https:\/\/doi.org\/10.1002\/mrm.28842","journal-title":"Magn Reson Med"},{"issue":"9","key":"6522_CR35","first-page":"1282","volume":"16","author":"K-L Li","year":"2023","unstructured":"Li K-L, Lewis D, Zhu X, Coope DJ, Djoukhadar I, King AT, Cootes T, Jackson A, Jefferson G (2023) A Novel Multi-Model High Spatial Resolution Method for Analysis of DCE MRI Data: Insights from Vestibular Schwannoma Responses to Antiangiogenic Therapy in Type II Neurofibromatosis. Pharm 16(9):1282","journal-title":"Pharm"},{"key":"6522_CR80","doi-asserted-by":"publisher","unstructured":"Lu S, Yin Z, Wu L et al (2024) Enhanced tumor control and hearing loss prevention achieved with combined immune checkpoint inhibitor and Anti-VEGF therapy in vestibular schwannoma model. bioRxiv Prepr Serv Biol. https:\/\/doi.org\/10.1101\/2024.12.29.630658","DOI":"10.1101\/2024.12.29.630658"},{"key":"6522_CR36","doi-asserted-by":"publisher","first-page":"e1118","DOI":"10.1097\/MAO.0000000000003224","volume":"42","author":"JP Marinelli","year":"2021","unstructured":"Marinelli JP, Carlson ML, Hunter JB, Nassiri AM, Haynes DS, Link MJ, Lohse CM, Reznitsky M, Stangerup S-E, Caye-Thomasen P (2021) Natural history of growing sporadic vestibular schwannomas during observation: an international multi-institutional study. Otol Neurotol 42:e1118\u2013e1124","journal-title":"Otol Neurotol"},{"issue":"8","key":"6522_CR37","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/neuonc\/noab303","volume":"24","author":"JP Marinelli","year":"2022","unstructured":"Marinelli JP, Schnurman Z, Killeen DE et al (2022) Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients. Neuro Oncol 24(8):1298\u20131306","journal-title":"Neuro Oncol"},{"issue":"2","key":"6522_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3171\/2016.5.JNS153013","volume":"127","author":"AP Marston","year":"2017","unstructured":"Marston AP, Jacob JT, Carlson ML, Pollock BE, Driscoll CLW, Link MJ (2017) Pretreatment growth rate as a predictor of tumor control following Gamma Knife radiosurgery for sporadic vestibular schwannoma. J Neurosurg 127(2):380\u2013387","journal-title":"J Neurosurg"},{"key":"6522_CR78","doi-asserted-by":"publisher","unstructured":"Meng Y, Lee MD, Berger A, Wiggins R, O\u2019Callaghan J, Bernstein K, Santhumayor B, Block KT, Fatterpekar G, Kondziolka D (2024) Understanding permeability changes in vestibular schwannomas as part of the dynamic response to radiosurgery using golden-angle radial sparse parallel imaging: a retrospective study. Neurosurgery. https:\/\/doi.org\/10.1227\/neu.0000000000003288","DOI":"10.1227\/neu.0000000000003288"},{"issue":"6","key":"6522_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/MAO.0b013e3182595454","volume":"33","author":"DA Moffat","year":"2012","unstructured":"Moffat DA, Kasbekar A, Axon PR, Lloyd SKW (2012) Growth characteristics of vestibular schwannomas. Otol Neurotol 33(6):1053\u20131058","journal-title":"Otol Neurotol"},{"key":"6522_CR74","doi-asserted-by":"publisher","unstructured":"\u00d6zer H, Yazol M, Erdo\u011fan N, Emmez \u00d6H, Kurt G, \u00d6ner AY (2022) Dynamic contrast-enhanced magnetic resonance imaging for evaluating early response to radiosurgery in patients with vestibular schwannoma. Jpn J Radiol. https:\/\/doi.org\/10.1007\/s11604-021-01245-y","DOI":"10.1007\/s11604-021-01245-y"},{"key":"6522_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2016.05.003","volume":"32","author":"I Paldor","year":"2016","unstructured":"Paldor I, Chen AS, Kaye AH (2016) Growth rate of vestibular schwannoma. J Clin Neurosci 32:1\u20138","journal-title":"J Clin Neurosci"},{"issue":"3","key":"6522_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1667\/RR2773.1","volume":"177","author":"HJ Park","year":"2012","unstructured":"Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311\u2013327","journal-title":"Radiat Res"},{"issue":"6","key":"6522_CR42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3171\/2019.7.JNS19879","volume":"133","author":"A Perry","year":"2019","unstructured":"Perry A, Graffeo CS, Carlstrom LP, Raghunathan A, Driscoll CLW, Neff BA, Carlson ML, Parney IF, Link MJ, Van Gompel JJ (2019) Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma. J Neurosurg 133(6):1637\u20131645","journal-title":"J Neurosurg"},{"issue":"2","key":"6522_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3171\/2022.4.JNS22203","volume":"138","author":"S Pikis","year":"2023","unstructured":"Pikis S, Mantziaris G, KormathAnand R et al (2023) Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a multi-institutional study. J Neurosurg 138(2):405\u2013412","journal-title":"J Neurosurg"},{"key":"6522_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2045-8118-12-5","volume":"12","author":"GL Pishko","year":"2015","unstructured":"Pishko GL, Muldoon LL, Pagel MA, Schwartz DL, Neuwelt EA (2015) Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS 12:5","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"6522_CR45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367","journal-title":"N Engl J Med"},{"issue":"6","key":"6522_CR46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046\u20131052","journal-title":"Otol Neurotol"},{"issue":"35","key":"6522_CR47","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A et al (2019) Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol 37(35):3446\u20133454","journal-title":"J Clin Oncol"},{"issue":"24","key":"6522_CR48","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, Bakker A, Fell G, Trippa L, Blakeley JO (2024) Brigatinib in NF2-related schwannomatosis with progressive tumors. N Engl J Med 390(24):2284\u20132294","journal-title":"N Engl J Med"},{"issue":"2","key":"6522_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1227\/01.NEU.0000194833.66593.8B","volume":"58","author":"BE Pollock","year":"2006","unstructured":"Pollock BE (2006) Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery 58(2):241\u2013246","journal-title":"Neurosurgery"},{"issue":"5","key":"6522_CR50","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/neuonc\/noaa230","volume":"23","author":"M Reznitsky","year":"2021","unstructured":"Reznitsky M, Petersen MMBS, West N, Stangerup S-E, Cay\u00e9-Thomasen P (2021) The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort. Neuro Oncol 23(5):827\u2013836","journal-title":"Neuro Oncol"},{"key":"6522_CR73","doi-asserted-by":"publisher","unstructured":"Sagers JE, Sahin MI, Moon IS, Ahmed SG, Stemmer-Rachamimov A, Brenner GJ, Stankovic KM (2019) NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. Hear Res. https:\/\/doi.org\/10.1016\/j.heares.2019.07.007","DOI":"10.1016\/j.heares.2019.07.007"},{"issue":"Suppl","key":"6522_CR51","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0385-8146(01)00078-5","volume":"28","author":"T Sakamoto","year":"2001","unstructured":"Sakamoto T, Fukuda S, Inuyama Y (2001) Hearing loss and growth rate of acoustic neuromas in follow-up observation policy. Auris Nasus Larynx 28(Suppl):S23\u2013S27","journal-title":"Auris Nasus Larynx"},{"issue":"3","key":"6522_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3171\/2019.5.JNS1923","volume":"133","author":"Z Schnurman","year":"2019","unstructured":"Schnurman Z, Nakamura A, McQuinn MW, Golfinos JG, Roland JT, Kondziolka D (2019) Volumetric growth rates of untreated vestibular schwannomas. J Neurosurg 133(3):742\u2013748","journal-title":"J Neurosurg"},{"issue":"2","key":"6522_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00004728-200303000-00024","volume":"27","author":"RN Sener","year":"2003","unstructured":"Sener RN (2003) Diffusion magnetic resonance imaging of solid vestibular schwannomas. J Comput Assist Tomogr 27(2):249\u2013252","journal-title":"J Comput Assist Tomogr"},{"issue":"2","key":"6522_CR54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MAO.0000000000002448","volume":"41","author":"M Sethi","year":"2019","unstructured":"Sethi M, Borsetto D, Cho Y et al (2019) The conditional probability of vestibular schwannoma growth at different time points after initial stability on an observational protocol. Otol Neurotol 41(2):250\u2013257","journal-title":"Otol Neurotol"},{"key":"6522_CR69","doi-asserted-by":"publisher","unstructured":"Sethi M, Borsetto D, Bance M, et al (2020) Determinants of Vestibular Schwannoma Growth. Otol Neurotol. https:\/\/doi.org\/10.1097\/MAO.0000000000003043","DOI":"10.1097\/MAO.0000000000003043"},{"issue":"1","key":"6522_CR55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1 -related schwannomatosis. Neurology 88(1):87\u201392","journal-title":"Neurology"},{"issue":"1","key":"6522_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","volume":"110","author":"CW Song","year":"2021","unstructured":"Song CW, Glatstein E, Marks LB, Emami B, Grimm J, Sperduto PW, Kim M-S, Hui S, Dusenbery KE, Cho LC (2021) Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. Int J Radiat Oncol Biol Phys 110(1):21\u201334","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"6522_CR57","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00701-021-04738-x","volume":"163","author":"P Soni","year":"2021","unstructured":"Soni P, Potter T, Poturalski M, Karakasis C, Borghei-Razavi H, Recinos PF, Kshettry VR, Lee J (2021) Pretreatment ADC predicts tumor control after Gamma Knife radiosurgery in solid vestibular schwannomas. Acta Neurochir (Wien) 163(4):1013\u20131019","journal-title":"Acta Neurochir (Wien)"},{"key":"6522_CR58","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/j.wneu.2019.08.193","volume":"132","author":"H Speckter","year":"2019","unstructured":"Speckter H, Santana J, Bido J, Hernandez G, Rivera D, Suazo L, Valenzuela S, Oviedo J, Gonzalez CF, Stoeter P (2019) Texture analysis of standard magnetic resonance images to predict response to gamma knife radiosurgery in vestibular schwannomas. World Neurosurg 132:e228\u2013e234","journal-title":"World Neurosurg"},{"issue":"Suppl 2","key":"6522_CR59","first-page":"e216","volume":"83","author":"D Stastna","year":"2022","unstructured":"Stastna D, Mannion R, Axon P et al (2022) Facial nerve function outcome and risk factors in resection of large cystic vestibular schwannomas. J Neurol Surg B Skull Base 83(Suppl 2):e216\u2013e224","journal-title":"J Neurol Surg B Skull Base"},{"key":"6522_CR70","doi-asserted-by":"publisher","unstructured":"Stastna D, Macfarlane R, Axon P et al (2024) Scoring System Assessing Risks of Growth in Sporadic Vestibular Schwannoma. Neurosurgery. https:\/\/doi.org\/10.1227\/neu.0000000000003170","DOI":"10.1227\/neu.0000000000003170"},{"key":"6522_CR75","doi-asserted-by":"publisher","unstructured":"Schouten Sammy SM, Lewis Daniel D, Cornelissen Stefan S, et al (2024) Dynamic contrast-enhanced and diffusion-weighted MR imaging for predicting tumor growth of sporadic vestibular schwannomas: a prospective study. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noae252","DOI":"10.1093\/neuonc\/noae252"},{"key":"6522_CR76","doi-asserted-by":"publisher","unstructured":"Stankovic KM, Batts S, Welling DB, Vasilijic S (2023) Immune profiling of secreted factors from human vestibular schwannoma cells and tumor-associated macrophages. Laryngoscope. https:\/\/doi.org\/10.1002\/lary.31067","DOI":"10.1002\/lary.31067"},{"issue":"3","key":"6522_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","volume":"10","author":"PS Tofts","year":"1999","unstructured":"Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T1- weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10(3):223\u2013232","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"6522_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.kint.2016.12.037","volume":"92","author":"GB Toth","year":"2017","unstructured":"Toth GB, Varallyay CG, Horvath A et al (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92(1):47\u201366","journal-title":"Kidney Int"},{"issue":"4","key":"6522_CR62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3171\/2011.12.JNS111662","volume":"116","author":"JK Varughese","year":"2012","unstructured":"Varughese JK, Breivik CN, Wentzel-Larsen T, Lund-Johansen M (2012) Growth of untreated vestibular schwannoma: a prospective study. J Neurosurg 116(4):706\u2013712","journal-title":"J Neurosurg"},{"issue":"2","key":"6522_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-021-03918-0","volume":"156","author":"J Wach","year":"2022","unstructured":"Wach J, G\u00fcresir \u00c1, Borger V et al (2022) Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma. J Neurooncol 156(2):365\u2013375","journal-title":"J Neurooncol"},{"issue":"3","key":"6522_CR64","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3171\/2020.7.JNS2044","volume":"135","author":"M Whitmeyer","year":"2021","unstructured":"Whitmeyer M, Brahimaj BC, Beer-Furlan A, Alvi S, Epsten MJ, Crawford F, Byrne RW, Wiet RM (2021) Resection of vestibular schwannomas after stereotactic radiosurgery: a systematic review. J Neurosurg 135(3):881\u2013889","journal-title":"J Neurosurg"},{"issue":"9","key":"6522_CR65","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, Di Tomaso E (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70(9):3483\u20133493","journal-title":"Cancer Res"},{"issue":"6","key":"6522_CR66","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3171\/2016.9.JNS161510","volume":"127","author":"CC Wu","year":"2017","unstructured":"Wu CC, Guo WY, Chung WY, Wu HM, Lin CJ, Lee CC, Du LK, Yang HC (2017) Magnetic resonance imaging characteristics and the prediction of outcome of vestibular schwannomas following Gamma Knife radiosurgery. J Neurosurg 127(6):1384\u20131391","journal-title":"J Neurosurg"},{"issue":"1","key":"6522_CR67","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/lary.29834","volume":"132","author":"H Yamada","year":"2022","unstructured":"Yamada H, Kai N, Hiratsuka Y et al (2022) Comparison of the signal intensity of vestibular schwannoma between growing and nongrowing tumors. Laryngoscope 132(1):198\u2013203","journal-title":"Laryngoscope"},{"key":"6522_CR68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.radonc.2020.10.041","volume":"155","author":"H-C Yang","year":"2021","unstructured":"Yang H-C, Wu C-C, Lee C-C, Huang H-E, Lee W-K, Chung W-Y, Wu H-M, Guo W-Y, Wu Y-T, Lu C-F (2021) Prediction of pseudoprogression and long-term outcome of vestibular schwannoma after Gamma Knife radiosurgery based on preradiosurgical MR radiomics. Radiother Oncol J Eur Soc Ther Radiol Oncol 155:123\u2013130","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"6522_CR71","doi-asserted-by":"publisher","unstructured":"Yang C, Alvarado D, Ravindran PK, Keizer ME, Hovinga K, Broen MPG, Kunst H (Dirk) PM, Temel Y (2024) Untreated Vestibular Schwannoma: Analysis of the Determinants of Growth. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16213718","DOI":"10.3390\/cancers16213718"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-025-06522-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-025-06522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T03:02:49Z","timestamp":1745290969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-025-06522-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6522"],"URL":"https:\/\/doi.org\/10.1007\/s00701-025-06522-7","relation":{},"ISSN":["0942-0940"],"issn-type":[{"value":"0942-0940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author DL and author ATK have previously received research support in the form of study drug from AMAG Pharmaceuticals and the Swedish Orphan Biovitrum (SOBI) respectively. The authors have no financial or proprietary interests in any material discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}